Outlook Therapeutics, Inc. — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Form 8-K filed 2026-07-24 reports Item 5.02 event (director/officer departure, election, or compensatory arrangement) as of 2026-07-21. No specific names, dollar amounts, equity grants, salary changes, or substantive details are visible in the filing header or metadata provided. The actual 8-K document text containing those specifics was not supplied for analysis.
Why this rating
Without substantive detail (names, amounts, roles), cannot assess materiality. Standard executive-change disclosure routine for $26.9M public company.
Extracted items
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.